scholarly journals Prognostic impact of K-RAS mutational status and primary tumour location in patients undergoing resection for colorectal cancer liver metastases: A METHEPAR analysis (multicentre study in Argentina)

2018 ◽  
Vol 29 ◽  
pp. v76
Author(s):  
J. O’Connor ◽  
E. Huertas ◽  
F. Sanchez Loria ◽  
F. Brancato ◽  
J. Grondona ◽  
...  
HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S56-S57
Author(s):  
R.M. Marcus ◽  
D.T. Fuentes ◽  
H.A. Lillemoe ◽  
A. Qayyum ◽  
T.A. Aloia

2013 ◽  
Vol 37 (11) ◽  
pp. 2647-2654 ◽  
Author(s):  
Hadrien Tranchart ◽  
Mircea Chirica ◽  
Matthieu Faron ◽  
Pierre Balladur ◽  
Leila Bengrine Lefevre ◽  
...  

2021 ◽  
pp. HEP40
Author(s):  
Giammaria Fiorentini ◽  
Donatella Sarti ◽  
Michele Nardella ◽  
Riccardo Inchingolo ◽  
Massimiliano Nestola ◽  
...  

Aims: Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status. Patients & methods: This was an observational multicentric case–control study (NCT03732235) on the efficacy and safety of B administered after TACE. Results: The disease control rate was significantly higher for the TACE + B than the TACE alone group (p < 0.001). KRAS wild-type patients had a significantly better disease control rate than those with KRAS mutations in the TACE + B group. Median OS and PFS were similar for the TACE + B and TACE groups, whereas median time to progression was significantly higher for the TACE + B group (p < 0.01). Conclusion: The combination of TACE with B may improve tumor response and delay disease progression.


2021 ◽  
pp. 030089162098346
Author(s):  
Guangzhe Pian ◽  
Sung Yeon Hong ◽  
Seung Yeop Oh

Introduction: Recently, a new inflammatory marker, the advanced lung cancer inflammation index (ALI), was reported as a prognostic marker in patients with several cancers. We aimed to investigate the prognostic value of ALI in patients with colorectal cancer liver metastases (CLM) undergoing surgery. Methods: From June 2009 to June 2018, 141 patients underwent a surgery for CLM at Ajou University Hospital, of whom 132 without extrahepatic metastases, systemic inflammatory diseases, or immune system diseases were enrolled in this study. The ALI was calculated using the following formula: ALI = body mass index × serum albumin/neutrophil-to-lymphocyte ratio. The patients were divided into high (n = 32) and low (n = 100) ALI groups according to the preoperative optimal cutoff value of 70.40 that was determined by X-tile software. Results: Patients with low ALI had a significantly worse overall survival (OS) compared to the high ALI group ( p = 0.010). Multivariate analysis showed that ALI and carcinoembryonic antigen (CEA) were independently associated with OS ( p = 0.009 and p = 0.042, respectively). Among the patients with CEA >5 ng/mL, the low ALI group had a significantly worse OS compared to the high ALI group ( p = 0.013). Conclusion: Preoperative ALI was a prognostic factor in patients with CLM undergoing surgery. In particular, the prognostic impact of ALI was more prominent in the patients with CEA >5 ng/mL.


Sign in / Sign up

Export Citation Format

Share Document